Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

Highlight

– In the phase 2 MUKDEN 05 trial (NCT05400993), neoadjuvant chidamide combined with sequential epirubicin–cyclophosphamide (EC) and docetaxel achieved a residual cancer burden (RCB) 0–I rate of 35.2% (19/54) in stage II–III, treatment-naïve HR+/HER2– breast cancer.

– The regimen was associated with frequent grade 3–4 hematologic toxicity (neutropenia 70%, leukopenia 67%); no treatment-related deaths were reported.